You are here : Home > DIABELOOP - Artificial pancreas for type-1 diabetics

Success | Micro-nanoelectronics

Success stories

DIABELOOP - Artificial pancreas for type-1 diabetics

​Diabeloop’s connected artificial pancreas will improve blood-sugar regulation and enhance quality of life for type-1 diabetics.

Published on 30 October 2018


Comprehensive and personalized system for autonomous T1D management

Diabeloop is a French independent company developing disruptive technological innovations to automate the treatment of Type one diabetes.

 Its first product, the DBLG1 System, is an integrated system that allows glycemic control in an automatic and highly efficient way. The core of this innovation is an Artificial Intelligence hosted on a terminal that connects via bluetooth with a continuous glucose meter (CGM) and an insulin pump.

 The algorithm makes and executes the many therapeutic decisions that the patients currently have to handle by themselves. Patients are only expected to log meals and physical activities.  


Partnered with the CERITD led by Doctor Charpentier, Diabeloop medical director and founder, and with CEA-Leti leading university diabetes centers (French and international), Diabeloop has formed a unique combination of expertise in medical research, clinical development and deep maths. Together, they have achieved a radical innovation, an algorithm that fine-tunes the glucose management in a proactive way thanks to personalization to the individuals physiology, self-learning capabilities and integration to patients' care path and everyday life.


​Resources and skills

Application sectors

Top page